Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $9.33

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price […]

Related Keywords

Monaco , ,Vanguard Group Inc ,Esperion Therapeutics Inc ,Bellevue Group ,Needham Company ,Nasdaq ,Armistice Capital ,Esperion Therapeutics ,Get Free Report ,Monaco Asset Management ,Asset Management ,Therapeutics Trading Down ,Get Free ,Esperion Therapeutics Daily ,